NAD+: The Complete Guide to the Longevity Coenzyme

Of all the compounds studied for their role in healthy aging, NAD+ stands out for one reason: its decline with age is not a side-effect of getting older, it may be one of the causes. Every cell in your body depends on it. Its absence impairs energy production, DNA repair, and the activity of the enzymes most closely linked to longevity. And for the first time, we have practical ways to restore it.

The science is genuinely compelling — and complicated. Here is what the evidence actually shows.

---

1. What is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It exists in two interconvertible forms: NAD+ (oxidised) and NADH (reduced), and its primary role is to shuttle electrons during metabolic reactions — making it central to how your cells generate energy.

But energy metabolism is only the beginning. NAD+ is also a substrate and signalling molecule for several critical classes of enzyme:

• Sirtuins (SIRT1–SIRT7): NAD+-dependent "longevity enzymes" that regulate DNA repair, mitochondrial function, inflammation, and cellular senescence
• PARPs (poly-ADP ribose polymerases): Use large quantities of NAD+ for DNA strand break repair
• CD38: A major NAD+-consuming enzyme that increases with age, accelerating the decline in NAD+ reserves

The central problem: NAD+ levels fall sharply with age. By some estimates, levels in a 60-year-old are 40–50% lower than in a 20-year-old. This decline reduces sirtuin activity, impairs DNA repair, and weakens mitochondrial function — compounding across every tissue in the body.

"NAD+ decline with age is not simply a correlation. The mechanisms linking low NAD+ to reduced cellular repair and longevity enzyme activity are among the best-characterised in ageing biology."

---

2. How it works

The sirtuin connection

Sirtuins are class III histone deacetylases — enzymes that use NAD+ to remove acetyl groups from target proteins, regulating their activity. They are activated by elevated NAD+ availability and are a central pathway through which caloric restriction and exercise extend healthy lifespan in animal models.

The seven mammalian sirtuins regulate:

• Mitochondrial biogenesis and function (SIRT1, SIRT3)
• DNA damage repair (SIRT1, SIRT6)
• Inflammation and oxidative stress (SIRT1, SIRT2)
• Metabolic efficiency and insulin sensitivity (SIRT1, SIRT4)
• Circadian rhythm and cellular senescence (SIRT1, SIRT6)
• Cardiovascular health (SIRT1, SIRT3, SIRT6)

As NAD+ levels decline with age, sirtuin activity diminishes — impairing DNA repair, antioxidant defence, and metabolic regulation in parallel.

NAD+ metabolism and precursors

The body synthesises NAD+ through three main pathways:

• De novo synthesis — from tryptophan via the kynurenine pathway
• Preiss-Handler pathway — from nicotinic acid (niacin)
• Salvage pathway — the dominant pathway in most tissues, recycling nicotinamide (NAM) back into NAD+ via NAMPT (the rate-limiting enzyme)

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) feed into the salvage pathway upstream of NAMPT, bypassing the rate-limiting step and efficiently raising intracellular NAD+ levels. This is why precursors are more effective at raising NAD+ than taking NAD+ directly — the coenzyme itself is poorly absorbed orally.

---

3. Research summary

Research level: Moderate. NAD+ precursors (NMN and NR) reliably elevate blood NAD+ in human trials. Evidence for metabolic, cardiovascular, and physical performance benefits is emerging from RCTs. A 2025 systematic review in Nature Metabolism concluded that clinical effectiveness for anti-aging outcomes in humans remains inconclusive, with encouraging but modest and inconsistent effect sizes across studies.

Key NMN studies

| Study | Population | Dose | Duration | Key finding | |-------|-----------|------|----------|-------------| | Yoshino et al. (2021, Science) | Overweight postmenopausal women with prediabetes | 250 mg/day | 10 weeks | 25% improvement in muscle insulin sensitivity vs placebo | | Yi et al. (2023, GeroScience) | Healthy middle-aged adults (n=80) | 300, 600, or 900 mg/day | 60 days | Dose-dependent NAD+ elevation; improved blood lipids and muscle function | | Liao et al. (2021, J Int Soc Sports Nutr) | Amateur runners | 600 or 1,200 mg/day | 6 weeks | Increased aerobic capacity | | Igarashi et al. (2022, npj Aging) | Healthy older men | 250 mg/day | 12 weeks | Increased NAD+ in peripheral blood; improved physical performance markers |

Key NR studies

| Study | Population | Dose | Duration | Key finding | |-------|-----------|------|----------|-------------| | Martens et al. (2018, Nat Commun) | Healthy middle-aged/older adults | 500 mg twice daily | 6 weeks | 60% increase in blood NAD+; 5 mmHg reduction in blood pressure; reduced arterial stiffness | | Elhassan et al. (2019, Cell Reports) | Healthy older adults | 1,000 mg/day | 21 days | Significant NAD+ elevation across multiple tissues | | Remie et al. (2020, Nat Commun) | Obese, metabolically compromised men | 1,000 mg/day | 6 weeks | No significant metabolic improvement vs placebo |

Proven vs speculative

| Claim | Evidence status | |-------|----------------| | NMN/NR raises blood NAD+ levels | Strong — consistent across multiple RCTs | | Improved insulin sensitivity (muscle) | Moderate — positive signal in one RCT (Yoshino 2021); not replicated at scale | | Reduced blood pressure / arterial stiffness | Moderate — NR 1,000 mg/day; one human trial | | Improved physical performance | Early — two RCTs with positive signals; small samples | | Anti-aging outcomes (longer healthspan) | Inconclusive — no human longevity endpoint data | | Extended lifespan | Animal data only |

---

4. Dosage guidance

Important: No standardised protocol has been validated through Western regulatory processes. The guidance below reflects the doses used in published human RCTs and supervised clinical practice. Individual response varies. Start at the lower end and titrate based on tolerance.

Evidence-based oral protocols

General wellness / NAD+ elevation:
  Supplement:  NMN or NR
  Dose:        250–500 mg/day
  Timing:      Morning, with or without food

Metabolic health / insulin sensitivity:
  Supplement:  NMN
  Dose:        250–500 mg/day
  Timing:      Morning

Cardiovascular / blood pressure:
  Supplement:  NR
  Dose:        500–1,000 mg/day
  Timing:      Split dose — morning and evening

Athletic performance:
  Supplement:  NMN
  Dose:        600–1,200 mg/day
  Timing:      Pre-training

Sublingual NMN

Dose:   125–250 mg
Method: Hold under tongue for 60–90 seconds before swallowing
Why:    Bypasses first-pass hepatic metabolism; estimated 2–6x oral bioavailability

IV NAD+ (clinic setting)

Loading:     3–5 sessions over 1–2 weeks
             500–1,000 mg per session over 2–4 hours
Maintenance: Monthly or quarterly top-up sessions

Start at lower doses — 125–250 mg/day — to assess tolerance before titrating upward. Some practitioners recommend cycling (5 days on, 2 days off), though this is not evidence-based.

---

5. Administration

Oral precursors (NMN and NR capsules)

The most practical option for home use with the best evidence base. Take in the morning, as NAD+ is involved in circadian rhythm signalling. Food does not significantly affect absorption.

Store capsules in a cool, dry location away from direct light. Quality varies significantly between brands; look for third-party testing certification.

Sublingual NMN

Sublingual delivery bypasses the liver's first-pass metabolism, increasing the proportion of NMN that reaches systemic circulation. Hold the powder or dissolve under the tongue for 60–90 seconds before swallowing. Some users find the taste unpleasant. Bioavailability advantage is real but not yet quantified in controlled human pharmacokinetic studies.

IV NAD+ infusions

IV infusions deliver NAD+ directly into the bloodstream, bypassing absorption entirely. Many patients report feeling effects during or shortly after the drip — increased energy and mental clarity are commonly described, though this is based on clinical observation rather than blinded trial data.

IV infusions are widely available at longevity and wellness clinics across Dubai and Abu Dhabi. Sessions typically run 2–4 hours. The evidence base for IV-specific benefits over oral precursors is weak; IV is primarily chosen for speed of effect and perceived intensity.

Practical note: For ongoing longevity support, oral NMN or NR offers the best evidence-to-cost ratio. IV infusions may be appropriate for periodic "loading" in a supervised protocol.

---

6. Safety and side effects

NAD+ precursors have a well-characterised safety profile from human clinical trials:

• NR well-tolerated at up to 2,000 mg/day for 12 weeks in RCTs
• NMN well-tolerated at doses up to 1,250 mg/day in human studies
• Most common adverse effects: mild GI discomfort (nausea, bloating, loose stools) at higher doses — dose-dependent and typically resolves with dose reduction

Drug interactions and cautions:

| Concern | Detail | |---------|--------| | Antihypertensive medications | NAD+ precursors may lower blood pressure; additive effect possible — monitor | | Diabetes medications | High-dose nicotinamide can reduce insulin sensitivity; monitor blood glucose | | Anticoagulants (warfarin) | Niacin-pathway metabolites may affect warfarin metabolism; monitor INR | | Chemotherapy / active cancer | NAD+ may enhance cancer cell survival; avoid during active oncology treatment unless cleared by oncologist | | Antidepressants (SSRIs/SNRIs) | Theoretical serotonin modulation; not well-studied | | Pregnancy and breastfeeding | Insufficient safety data; not recommended | | Liver disease | Check liver function before starting, particularly with significant alcohol use |

Theoretical concern — tumour promotion: Elevated NAD+ fuels all rapidly dividing cells, including malignant ones. This remains under investigation and has not manifested as a signal in clinical trials to date, but long-term use without clinical monitoring is not advisable.

---

7. Who should consider this

Most relevant for:

Adults 40+ interested in longevity science The mechanistic case for addressing NAD+ decline in the context of aging is among the best-supported in the field. If you are committed to a serious, evidence-informed longevity protocol, NMN or NR belongs in the conversation.

Individuals with metabolic health goals The insulin sensitivity data from Yoshino (2021) is the most compelling specific outcome in the NMN literature. For metabolically compromised individuals or those managing prediabetes, NMN at 250–500 mg/day has a reasonable evidence base.

Active individuals focused on performance and recovery Two RCTs show improved aerobic capacity and physical performance with NMN supplementation. If your protocol already includes recovery-focused peptides like BPC-157 or TB-500, NAD+ adds a complementary cellular energy dimension.

Those with access to IV wellness clinics in the UAE IV NAD+ is widely available in Dubai and Abu Dhabi. If periodic high-dose loading appeals and cost is not the primary concern, IV sessions offer the highest bioavailability and fastest subjective effect — though the evidence base for clinical superiority over oral precursors is not established.

Less relevant for:

• Acute physical injury recovery (BPC-157/TB-500 have more targeted mechanisms for this)
• Weight loss as a primary goal (GLP-1 receptor agonists have a much stronger evidence base)
• Anyone seeking FDA-validated therapeutic outcomes — no NAD+ precursor is approved as a drug

---

8. NMN vs NR: which precursor?

| Factor | NMN | NR | |--------|-----|----| | Molecular weight | 334 Da | 255 Da | | Pathway | Directly to NAD+ via NMNAT enzymes | Converted to NMN first, then NAD+ | | Evidence base | Growing rapidly; more recent large RCTs | More established; earlier to market | | Tissue specificity | Especially effective in muscle and liver | Broad tissue distribution | | Cost | Generally higher | Lower; more established supply chain | | UAE availability | Wide (Amazon.ae, Noon, Aster, Life Pharmacy) | Less common in UAE |

Stack combinations: Many practitioners pair NAD+ precursors with:

• Resveratrol or pterostilbene — SIRT1 activators that theoretically synergise with elevated NAD+ to amplify sirtuin pathway activity
• TMG (trimethylglycine) — to counter potential methyl group depletion associated with NAD+ metabolism, at 500–1,000 mg/day

---

9. Related peptides

Epithalon — Epithalon targets telomere biology and the neuroendocrine axis, while NAD+ supports the sirtuin/PARP arm of cellular longevity and mitochondrial energy metabolism. They work through distinct but complementary mechanisms and are often combined in comprehensive longevity protocols. They do not appear to interact.

GHK-Cu — GHK-Cu is a copper-binding tripeptide with gene-modulation, anti-inflammatory, and tissue-repair activity. It shares some longevity rationale with NAD+ through overlapping effects on antioxidant pathways and cellular maintenance, but works via different mechanisms and is particularly relevant for skin and connective tissue.

---

This guide is for research and educational purposes only. NAD+ precursors are sold as dietary supplements, not approved therapeutic agents for aging or disease. Any consideration of IV NAD+ or high-dose supplementation protocols should involve consultation with a qualified clinician. SEQUENCE does not provide medical advice.

Ready to build your protocol? Take the SEQUENCE quiz →